RAPID ANTIVIRAL DNA-DNA HYBRIDIZATION ASSAY FOR HUMAN CYTOMEGALOVIRUS

被引:57
作者
DANKNER, WM
SCHOLL, D
STANAT, SC
MARTIN, M
SONKE, RL
SPECTOR, SA
机构
[1] UNIV CALIF SAN DIEGO,MED CTR,DEPT PEDIAT,225 DICKINSON ST,H-814-H,LA JOLLA,CA 92093
[2] DIAGNOST HYBRIDS INC,RES TRIANGLE PK,NC
[3] BURROUGHS WELLCOME CO,DEPT VIROL,RES TRIANGLE PK,NC 27709
[4] UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093
[5] OHIO UNIV,DEPT ZOOL & BIOMED SCI,ATHENS,OH 45701
关键词
Antiviral assay; DNA-DNA hybridization; Ganciclovir; Human cytomegalovirus;
D O I
10.1016/0166-0934(90)90122-V
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A rapid DNA-DNA hybridization technique that can be accomplished in 4 to 5 days was compared with plaque reduction assay to determine its reliability in performing antiviral assays for human cytomegalovirus (HCMV). The assay involves lysing infected cells, direct wicking of denatured DNA onto membranes and hybridization using a 125I-labeled HCMV DNA probe. Using ten ganciclovir sensitive clinical HCMV strains for comparison, the DNA hybridization technique correlated well with the plaque assay. Clinical HCMV strains previously identified as resistant to ganciclovir were also readily identified. The DNA-DNA hybridization assay is less tedious and more rapid than plaque reduction assays, and thus, provides an excellent alternative for evaluation of the antiviral activity of drugs against HCMV. © 1990.
引用
收藏
页码:293 / 298
页数:6
相关论文
共 11 条
[1]  
BETTS RF, 1982, PROG MED VIROL, V28, P44
[2]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[3]   GANCICLOVIR TREATMENT OF CYTOMEGALOVIRUS DISEASE IN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED HOSTS [J].
ERICE, A ;
JORDAN, C ;
CHACE, BA ;
FLETCHER, C ;
CHINNOCK, BJ ;
BALFOUR, HH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (22) :3082-3087
[4]   PROGRESSIVE DISEASE DUE TO GANCICLOVIR-RESISTANT CYTOMEGALO-VIRUS IN IMMUNOCOMPROMISED PATIENTS [J].
ERICE, A ;
CHOU, S ;
BIRON, KK ;
STANAT, SC ;
BALFOUR, HH ;
JORDAN, MC .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (05) :289-293
[5]   NUCLEIC-ACID HYBRIDIZATION FOR MEASUREMENT OF EFFECTS OF ANTIVIRAL COMPOUNDS ON HUMAN CYTOMEGALOVIRUS DNA-REPLICATION [J].
GADLER, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 24 (03) :370-374
[6]   SERIOUS CYTOMEGALO-VIRUS DISEASE IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) [J].
JACOBSON, MA ;
MILLS, J .
ANNALS OF INTERNAL MEDICINE, 1988, 108 (04) :585-594
[7]   GANCICLOVIR FOR THE TREATMENT AND SUPPRESSION OF SERIOUS INFECTIONS CAUSED BY CYTOMEGALOVIRUS [J].
LASKIN, OL ;
CEDERBERG, DM ;
MILLS, J ;
ERON, LJ ;
MILDVAN, D ;
SPECTOR, SA .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (02) :201-207
[8]   DISEASES PRODUCED BY CYTOMEGALOVIRUSES [J].
NANKERVIS, GA ;
KUMAR, ML .
MEDICAL CLINICS OF NORTH AMERICA, 1978, 62 (05) :1021-1035
[9]  
SPECTOR SA, 1985, CLIN CHEM, V31, P1514
[10]   EFFECTS OF ACYCLOVIR COMBINED WITH OTHER ANTIVIRAL AGENTS ON HUMAN CYTOMEGALOVIRUS [J].
SPECTOR, SA ;
TYNDALL, M ;
KELLEY, E .
AMERICAN JOURNAL OF MEDICINE, 1982, 73 (1A) :36-39